Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
![AI](https://streamlined.nyc3.cdn.digitaloceanspaces.com/assets/ai-default.gif)
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Johnson & Johnson
Johnson & Johnson News
Johnson & Johnson Quantitative Score
![Website screenshot](https://streamlined.nyc3.cdn.digitaloceanspaces.com/website-screenshots/jnj-com.webp)
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson Earnings & Revenue
Johnson & Johnson Financials
Table Compare
Compare JNJ metrics with: | |||
---|---|---|---|
Earnings & Growth | JNJ | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | JNJ | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | JNJ | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | JNJ | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Johnson & Johnson Income
Johnson & Johnson Balance Sheet
Johnson & Johnson Cash Flow
Johnson & Johnson Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Strong Buy |
Return on Assets | Strong Buy |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Johnson & Johnson Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 4.8600 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-09-10 | 1.24 | Quarterly |
2024-06-04 | 1.24 | Quarterly |
2024-03-05 | 1.19 | Quarterly |
2023-12-05 | 1.19 | Quarterly |
2023-09-07 | 1.19 | Quarterly |
Historical Market Cap
Shares Outstanding
Johnson & Johnson Executives
Name | Role |
---|---|
Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, R&D |
Mr. Joaquin Duato | Chief Executive Officer & Chairman |
Mr. Joseph J. Wolk CPA | Executive Vice President & Chief Financial Officer |
Ms. Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine |
Dr. Peter M. Fasolo Ph.D. | Executive Vice President & Chief Human Resources Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, R&D | 1958 | 8.57M | |
Mr. Joaquin Duato | Chief Executive Officer & Chairman | Male | 1963 | 6.21M |
Mr. Joseph J. Wolk CPA | Executive Vice President & Chief Financial Officer | Male | 1967 | 3.17M |
Ms. Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine | Female | 1964 | 3.1M |
Dr. Peter M. Fasolo Ph.D. | Executive Vice President & Chief Human Resources Officer | 1963 | 2.15M |
Johnson & Johnson Insider Trades
Date | 30 Aug |
Name | Decker Robert J |
Role | VP Corporate Controller |
Transaction | Acquired |
Type | M-Exempt |
Shares | 5635 |
Date | 30 Aug |
Name | Decker Robert J |
Role | VP Corporate Controller |
Transaction | Disposed |
Type | S-Sale |
Shares | 5635 |
Date | 30 Aug |
Name | Decker Robert J |
Role | VP Corporate Controller |
Transaction | Disposed |
Type | M-Exempt |
Shares | 5635 |
Date | 8 Jul |
Name | Broadhurst Vanessa |
Role | EVP, Global Corp Affairs |
Transaction | Acquired |
Type | M-Exempt |
Shares | 9809 |
Date | 8 Jul |
Name | Broadhurst Vanessa |
Role | EVP, Global Corp Affairs |
Transaction | Disposed |
Type | F-InKind |
Shares | 5018 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
30 Aug | Decker Robert J | VP Corporate Controller | Acquired | M-Exempt | 5635 |
30 Aug | Decker Robert J | VP Corporate Controller | Disposed | S-Sale | 5635 |
30 Aug | Decker Robert J | VP Corporate Controller | Disposed | M-Exempt | 5635 |
8 Jul | Broadhurst Vanessa | EVP, Global Corp Affairs | Acquired | M-Exempt | 9809 |
8 Jul | Broadhurst Vanessa | EVP, Global Corp Affairs | Disposed | F-InKind | 5018 |